CA
NZ
UK
AU
IND
US
…
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
argenx SE is a biopharmaceutical company developing antibody-based therapies for autoimmune and neuromuscular diseases; its lead asset, the FcRn blocker efgartigimod, has received regulatory approvals and is in early commercial rollout. Long-term growth may be driven by label expansions across autoimmune indications, commercialization scale-up, and additional pipeline candidates discovered through its antibody platform that could support multiple new assets.
Key risks include commercial execution and reimbursement challenges for efgartigimod, competition from other immunotherapies, clinical and regulatory setbacks for pipeline programs, and potential financing needs if revenues do not scale as expected.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1278.61M | 85.18M | -304.50M | -729.31M | -399.74M |
| Net income | 1292.04M | 833.04M | -295.05M | -709.59M | -408.26M |
| Selling general administrative | 1359.98M | 1052.19M | 709.54M | 472.13M | 307.64M |
| Gross profit | 3702.82M | 1962.94M | 1108.48M | 381.31M | - |
| Reconciled depreciation | 28.10M | 17.53M | 111.31M | 104.34M | 5.87M |
| Ebit | - | - | - | -723.92M | -359.90M |
| Ebitda | - | - | - | -725.41M | -354.03M |
| Operating income | 1054.62M | -17.84M | -420.64M | -719.66M | -359.90M |
| Other operating expenses | - | - | - | - | 17.02M |
| Interest expense | 4.08M | 2.46M | 0.91M | 3.91M | 1.10M |
| Tax provision | -13.43M | -747.86M | -9.44M | -19.72M | 8.52M |
| Interest income | 163.09M | 157.51M | 107.39M | 27.66M | 3.49M |
| Net interest income | 159.01M | 155.04M | 106.48M | 23.76M | 2.39M |
| Income tax expense | - | - | - | -19.72M | 8.52M |
| Total revenue | 4153.48M | 2190.23M | 1226.32M | 410.75M | 497.28M |
| Total operating expenses | 3098.87M | 2208.07M | 1646.95M | 1130.41M | 857.17M |
| Cost of revenue | 450.67M | 227.29M | 117.83M | 29.43M | - |
| Total other income expense net | 64.98M | -52.02M | 9.66M | -33.41M | -42.24M |
| Net income from continuing ops | 1292.04M | 833.04M | -295.05M | -709.59M | -408.26M |
| Net income applicable to common shares | - | - | - | -709.59M | -408.26M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 8682.70M | 6202.52M | 4542.46M | 3134.26M | 2850.27M |
| Intangible assets | 272.10M | 181.44M | 125.23M | 174.90M | 171.68M |
| Other current assets | - | - | - | -0.00M | - |
| Total liab | 1359.61M | 704.24M | 444.95M | 320.56M | 316.05M |
| Total stockholder equity | 7323.09M | 5498.28M | 4097.51M | 2813.70M | 2534.22M |
| Other current liab | - | - | - | 6.32M | 5.14M |
| Common stock | - | - | - | 6.64M | 6.23M |
| Capital stock | 7.35M | 7.23M | 7.06M | 6.64M | 6.23M |
| Retained earnings | -279.77M | -1571.80M | -2404.84M | -2109.79M | -1400.20M |
| Other liab | - | - | - | 9.28M | 6.86M |
| Other assets | - | - | - | 128.45M | 66.61M |
| Cash | 3491.29M | 1499.94M | 2048.84M | 800.74M | 1334.68M |
| Total current liabilities | 1320.19M | 669.92M | 422.99M | 302.28M | 301.24M |
| Other stockholder equity | - | - | - | 606.97M | 465.41M |
| Property plant equipment | - | - | - | 16.23M | 15.84M |
| Total current assets | 6899.10M | 4883.10M | 4123.74M | 2774.20M | 2542.97M |
| Long term investments | 50.53M | 49.70M | 47.16M | 40.48M | 53.17M |
| Net tangible assets | - | - | - | 2638.80M | 2362.54M |
| Short term investments | 948.75M | 1878.89M | 1131.00M | 1391.81M | 1002.05M |
| Net receivables | 1489.57M | 817.71M | 417.99M | 277.27M | 38.22M |
| Inventory | 473.53M | 407.23M | 310.55M | 228.35M | 109.08M |
| Accounts payable | 554.27M | 482.70M | 245.56M | 188.72M | 208.85M |
| Non currrent assets other | 4.84M | 1.96M | 2.42M | 1.74M | 1.71M |
| Non current assets total | 1783.59M | 1319.42M | 418.72M | 360.06M | 307.30M |
| Capital lease obligations | 47.16M | 39.05M | 20.00M | 12.43M | 11.46M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 939.51M | -753.94M | 308.21M | -370.51M | -228.24M |
| Change to liabilities | - | - | - | 0.33M | -180.47M |
| Total cashflows from investing activities | - | - | - | -461.18M | -347.07M |
| Net borrowings | -4.11M | -7.64M | -3.80M | -4.17M | -3.85M |
| Total cash from financing activities | 233.01M | 279.76M | 1336.73M | 843.76M | 1121.34M |
| Change to operating activities | - | - | - | -34.51M | -44.97M |
| Net income | 1292.04M | 792.72M | -272.33M | -709.59M | -408.26M |
| Change in cash | 1902.21M | -520.58M | 1224.61M | -533.94M | 117.87M |
| Begin period cash flow | 1499.94M | 2048.84M | 800.74M | 1334.68M | 1216.80M |
| End period cash flow | 3491.29M | 1499.94M | 2048.84M | 800.74M | 1334.68M |
| Total cash from operating activities | 685.19M | -82.75M | -420.33M | -862.81M | -606.81M |
| Issuance of capital stock | 0.00M | 0.00M | 1196.73M | 760.95M | 1091.33M |
| Depreciation | 28.10M | 17.53M | 111.31M | 103.63M | 5.40M |
| Other cashflows from investing activities | - | - | - | 13.14M | 2.60M |
| Change to inventory | -98.95M | -96.00M | -83.03M | -119.28M | -83.88M |
| Change to account receivables | - | - | - | -222.26M | -31.63M |
| Other cashflows from financing activities | - | - | - | -0.37M | 0.44M |
| Change to netincome | - | - | - | 118.17M | 136.54M |
| Capital expenditures | 111.68M | 68.30M | 43.81M | 0.84M | 3.62M |
| Change in working capital | -422.63M | -325.17M | -308.89M | -375.72M | -340.95M |
| Stock based compensation | 248.08M | 235.18M | 232.97M | 157.03M | 179.37M |
| Other non cash items | 31.63M | -0.28M | 2.07M | - | -75.00M |
| Free cash flow | 573.51M | -151.05M | -464.14M | -966.63M | -728.25M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
| NVO Novo Nordisk A/S |
0.08 0.20% |
39.13 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.44 1.23% |
517.49 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.65 0.33% |
807.67 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| CMXHF CSL Limited |
- -% |
136.90 | - | 18.87 | 3.71 | 3.96 | 4.35 | 10.84 |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
| Name | Title | Year Born |
|---|---|---|
| Ms. Malini Moorthy | Gen. Counsel | 1970 |
| Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MSc | CEO & Exec. Director | 1972 |
| Prof. Hans de Haard Ir, Ph.D. | Co-Founder & Chief Scientific Officer | 1960 |
| Mr. Karl Gubitz | Chief Financial Officer | 1970 |
| Mr. R. Keith Woods | Chief Operating Officer | 1968 |
| Mr. Arjen Lemmen M.Sc. | VP of Corp. Devel. & Strategy | 1985 |
| Dr. David L. Lacey M.D. | Advisor | 1952 |
| Ms. Andria Wilk | Global Head of Quality | 1974 |
| Mr. Filip Borgions | VP & Global Head of Technical Operations | NA |
| Ms. Beth DelGiacco | VP and Global Head of Corp. Communications & Investor Relations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.70%
Consumer Cyclical
-0.35%
Consumer Defensive
-0.54%
Energy
+0.40%
Financial Services
-0.54%
Financials
+0.30%
Healthcare
+0.19%
Industrials
+0.38%
Real Estate
+0.22%
Technology
+0.27%
Utilities
-0.53%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...